D.E. Shaw & Co’s Amgen AMGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$34M Sell
96,500
-24,400
-20% -$8.7M 0.02% 852
2025
Q4
$39.6M Buy
120,900
+13,100
+12% +$4.16M 0.02% 833
2025
Q3
$30.4M Sell
107,800
-152,900
-59% -$44.3M 0.02% 912
2025
Q2
$72.8M Buy
260,700
+135,600
+108% +$38.4M 0.05% 429
2025
Q1
$39M Sell
125,100
-34,800
-22% -$10.3M 0.03% 587
2024
Q4
$41.7M Sell
159,900
-98,000
-38% -$29.1M 0.03% 650
2024
Q3
$83.1M Sell
257,900
-17,400
-6% -$5.69M 0.07% 328
2024
Q2
$86M Buy
275,300
+75,300
+38% +$22.1M 0.08% 297
2024
Q1
$56.9M Buy
200,000
+95,000
+90% +$27.8M 0.05% 438
2023
Q4
$30.2M Sell
105,000
-27,800
-21% -$7.57M 0.03% 686
2023
Q3
$35.7M Buy
132,800
+30,000
+29% +$7.49M 0.04% 561
2023
Q2
$22.8M Buy
102,800
+42,800
+71% +$9.93M 0.02% 799
2023
Q1
$14.5M Buy
60,000
+30,000
+100% +$7.36M 0.02% 1100
2022
Q4
$7.88M Buy
+30,000
New +$8.04M 0.01% 1663
2022
Q3
Sell
-101,600
Closed -$24.7M 5154
2022
Q2
$24.7M Buy
101,600
+4,200
+4% +$1.03M 0.03% 732
2022
Q1
$23.6M Sell
97,400
-500
-0.5% -$115K 0.02% 919
2021
Q4
$22M Buy
97,900
+11,100
+13% +$2.34M 0.02% 1017
2021
Q3
$18.5M Sell
86,800
-43,200
-33% -$9.94M 0.02% 1071
2021
Q2
$31.7M Buy
130,000
+90,000
+225% +$22.1M 0.03% 774
2021
Q1
$9.95M Buy
40,000
+37,600
+1,567% +$8.97M 0.01% 1353
2020
Q4
$552K Hold
2,400
﹤0.01% 3340
2020
Q3
$610K Sell
2,400
-12,000
-83% -$2.97M ﹤0.01% 3124
2020
Q2
$3.4M Sell
14,400
-147,400
-91% -$33.6M ﹤0.01% 1977
2020
Q1
$32.8M Sell
161,800
-18,000
-10% -$3.93M 0.05% 414
2019
Q4
$43.3M Buy
179,800
+113,600
+172% +$25M 0.05% 459
2019
Q3
$12.8M Buy
+66,200
New +$12.7M 0.02% 1015
2019
Q2
Sell
-40,000
Closed -$7.6M 3651
2019
Q1
$7.6M Buy
40,000
+33,700
+535% +$6.44M 0.01% 1278
2018
Q4
$1.23M Sell
6,300
-75,600
-92% -$14.7M ﹤0.01% 2522
2018
Q3
$17M Sell
81,900
-26,800
-25% -$5.28M 0.02% 844
2018
Q2
$20.1M Buy
+108,700
New +$19.2M 0.03% 722
2018
Q1
Sell
-133,200
Closed -$23.2M 3466
2017
Q4
$23.2M Buy
133,200
+92,200
+225% +$16.3M 0.03% 621
2017
Q3
$7.64M Sell
41,000
-44,700
-52% -$7.92M 0.01% 1100
2017
Q2
$14.8M Sell
85,700
-48,500
-36% -$7.89M 0.02% 717
2017
Q1
$22M Sell
134,200
-68,400
-34% -$11.4M 0.04% 529
2016
Q4
$29.6M Sell
202,600
-121,600
-38% -$18.3M 0.05% 472
2016
Q3
$54.1M Buy
324,200
+220,800
+214% +$37.3M 0.1% 255
2016
Q2
$15.7M Sell
103,400
-90,400
-47% -$14.1M 0.03% 639
2016
Q1
$29.1M Sell
193,800
-111,900
-37% -$16.6M 0.05% 414
2015
Q4
$49.6M Buy
305,700
+97,200
+47% +$15.3M 0.07% 317
2015
Q3
$28.8M Buy
208,500
+2,400
+1% +$378K 0.04% 474
2015
Q2
$31.6M Sell
206,100
-13,900
-6% -$2.23M 0.05% 463
2015
Q1
$35.2M Sell
220,000
-24,300
-10% -$3.83M 0.05% 398
2014
Q4
$38.9M Sell
244,300
-185,100
-43% -$28.8M 0.05% 447
2014
Q3
$60.3M Sell
429,400
-80,900
-16% -$10.6M 0.08% 292
2014
Q2
$60.4M Sell
510,300
-39,300
-7% -$4.55M 0.08% 278
2014
Q1
$67.8M Buy
549,600
+7,300
+1% +$885K 0.1% 220
2013
Q4
$61.9M Sell
542,300
-196,600
-27% -$22.4M 0.08% 246
2013
Q3
$82.7M Buy
738,900
+255,200
+53% +$27.7M 0.13% 162
2013
Q2
$47.7M Buy
+483,700
New +$50.2M 0.09% 233

Other funds holding AMGN

D.E. Shaw & Co's AMGN Position: Q1 2026 in Review

D.E. Shaw & Co increased its Amgen (AMGN) stake by 514% in Q1 2026, buying an estimated $53.1M and bringing the position to 178,009 shares worth $62.6M. The position accounts for 0.04% of the portfolio, ranked #569.

D.E. Shaw & Co first reported a position in AMGN in Q2 2013 and has held it in 52 quarters since. The position peaked at $515M in Q4 2024. 3,125 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.

  • D.E. Shaw & Co held 178,009 shares of Amgen worth $62.6M as of Q1 2026.
  • D.E. Shaw & Co bought 149,032 Amgen shares in Q1 2026, an estimated $53.1M.
  • Amgen made up 0.04% of D.E. Shaw & Co's portfolio in Q1 2026, its #569 holding.
  • D.E. Shaw & Co first reported a position in Amgen in Q2 2013 and has held it in 52 quarters since.
  • D.E. Shaw & Co's Amgen position peaked at $515M in Q4 2024.
  • 3,125 funds tracked by Wall St. Rank held Amgen as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.